Cornerstone Pharmaceuticals
10 clinical trials · Sponsor
◉ Watch Cornerstone Pharmaceuticals
| Record | Firm | Date |
|---|---|---|
| Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer (NCT06518538) | Cornerstone Pharmaceuticals | 2024-08-15 |
| CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (NCT05070104) | Cornerstone Pharmaceuticals | 2023-03-30 |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue (NCT04593758) | Cornerstone Pharmaceuticals | 2021-09-01 |
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML (NCT03504410) | Cornerstone Pharmaceuticals | 2018-11-12 |
| Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (NCT03504423) | Cornerstone Pharmaceuticals | 2018-11-09 |
Track Cornerstone Pharmaceuticals automatically
Every clearance here is in the API, with alerts when new ones post.